Amantadine/Oseltamivir/Ribavirin

金刚烷胺/奥司他韦/利巴韦林

Report date: 2022/12/07 17:07:45

Base Information

Drug NameAmantadine/Oseltamivir/Ribavirin
Drug Alias NameOseltamivir/ribavirin /amantadine奥司他韦/金刚烷胺/利巴韦林Amantadine/ribavirine/oseltamivir金刚烷胺/利巴韦林/奥司他韦Ribavirin/oseltamivir/amantadine +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsNeuraminidase inhibitorsmRNA guanylyltransferase inhibitors +[5] 
TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Glutamate [NMDA] receptorNeuraminidase +[5] 
Therapy Area/IndicationsInfluenza A virus infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Amantadine HydrochlorideRibavirinOseltamivir Phosphate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthAdamas Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInfluenza A virus infections

Other Information

ATC CodeN/A
Related LinksN/A